The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Open accessAbstract
The SARS-CoV-2 main protease (M pro ) is the drug target of Pfizer’s oral drug Paxlovid. The emergence of SARS-CoV-2 variants with mutations in M pro raised the alarm of potential drug resistance. In this study, we identified 100 naturally occurring M pro mutations located at the nirmatrelvir binding site, among which 20 mutants, including S144M/F/A/G/Y, M165T, E166G, H172Q/F, and Q192T/S/L/A/I/P/H/V/W/C/F, showed comparable enzymatic activity to the wild-type (k cat /K m <10-fold change) and resistance to nirmatrelvir (K i >10-fold increase). X-ray crystal structures were determined for seven representative mutants with and/or without GC-376/nirmatrelvir. Viral growth assay showed that M pro mutants with reduced enzymatic activity led to attenuated viral replication. Overall, our study identified several drug resistant hot spots that warrant close monitoring for possible clinical evidence of Paxlovid resistance. One Sentence Summary Paxlovid resistant SARS-CoV-2 viruses with mutations in the main protease have been identified from clinical isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.042 · Cited by 1,488
Ma, C., Sacco, M. D., Hurst, B., Townsend, J. A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M. T., Chen, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0356-z · Cited by 880
Self-citationThe PDB_REDO server for macromolecular structure model optimization
Joosten, R. P., Long, F., Murshudov, G. N., & Perrakis, A. (2014) · IUCrJ · doi:10.1107/s2052252514009324 · Cited by 834
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A.-C., et al. (2023) · Nature · doi:10.1038/s41586-022-05514-2 · Cited by 480
Sacco, M. D., Ma, C., Lagarias, P., Gao, A., Townsend, J. A., Meng, X., Dube, P., Zhang, X., Hu, Y., Kitamura, N., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe0751 · Cited by 385
Self-citationKuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., et al. (2008) · Hepatology · doi:10.1002/hep.22549 · Cited by 349
Boras, B., Jones, R. M., Anson, B. J., Arenson, D., Aschenbrenner, L., Bakowski, M. A., Beutler, N., Binder, J., Chen, E., Eng, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26239-2 · Cited by 280
Self-citationKim, Y., Liu, H., Galasiti Kankanamalage, A. C., Weerasekara, S., Hua, D. H., Groutas, W. C., Chang, K.-O., & Pedersen, N. C. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005531 · Cited by 238
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Zhou, Y., Gammeltoft, K. A., Ryberg, L. A., Pham, L. V., Tjørnelund, H. D., Binderup, A., Duarte Hernandez, C. R., Fernandez-Antunez, C., Offersgaard, A., Fahnøe, U., et al. (2022) · Science Advances · doi:10.1126/sciadv.add7197 · Cited by 219
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
Ullrich, S., Ekanayake, K. B., Otting, G., & Nitsche, C. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128629 · Cited by 190
Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants
Greasley, S. E., Noell, S., Plotnikova, O., Ferre, R., Liu, W., Bolanos, B., Fennell, K., Nicki, J., Craig, T., Zhu, Y., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101972 · Cited by 190
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Moghadasi, S. A., Heilmann, E., Khalil, A. M., Nnabuife, C., Kearns, F. L., Ye, C., Moraes, S. N., Costacurta, F., Esler, M. A., Aihara, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade8778 · Cited by 187
Hu, Y., Meng, X., Zhang, F., Xiang, Y., & Wang, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1888660 · Cited by 184
Self-citationJochmans, D., Liu, C., Donckers, K., Stoycheva, A., Boland, S., Stevens, S. K., De Vita, C., Vanmechelen, B., Maes, P., Trüeb, B., et al. (2023) · mBio · doi:10.1128/mbio.02815-22 · Cited by 167
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
Kitamura, N., Sacco, M. D., Ma, C., Hu, Y., Townsend, J. A., Meng, X., Zhang, F., Zhang, X., Ba, M., Szeto, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00509 · Cited by 164
Self-citationHeilmann, E., Costacurta, F., Moghadasi, S. A., Ye, C., Pavan, M., Bassani, D., Volland, A., Ascher, C., Weiss, A. K. H., Bante, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq7360 · Cited by 145
Xiong, M., Su, H., Zhao, W., Xie, H., Shao, Q., & Xu, Y. (2021) · Medicinal Research Reviews · doi:10.1002/med.21783 · Cited by 139
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance
Shaqra, A. M., Zvornicanin, S. N., Huang, Q. Y. J., Lockbaum, G. J., Knapp, M. S., Tandeske, L., Bakan, D. T., Flynn, J. M., Bolon, D. N. A., Moquin, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31210-w · Cited by 131
Noske, G. D., Silva, E. D. S., de Godoy, M. O., Dolci, I., Fernandes, R. S., Guido, R. V. C., Sjö, P., Oliva, G., & Godoy, A. S. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.103004 · Cited by 130
Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
Flynn, J. M., Samant, N., Nachum, G. S., Barkan, D. T., Yılmaz, N. K., Schiffer, C. A., Moquin, S. A., Dovala, D., & Bolon, D. N. A. (2022) · eLife · doi:10.7554/elife.77433 · Cited by 129
Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008–2010
Sheu, T. G., Fry, A. M., Garten, R. J., Deyde, V., Shwe, T., Bullion, L., Peebles, P. J., Li, Y., Klimov, A. I., & Gubareva, L. V. (2010) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq005 · Cited by 128
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir
Yang, K. S., Leeuwon, S. Z., Xu, S., & Liu, W. R. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00404 · Cited by 117
Hu, Y., Ma, C., Szeto, T., Hurst, B. L., Tarbet, E. B., & Wang, J. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00761 · Cited by 116
Self-citationSARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies
Tan, B., Joyce, R., Tan, H., Hu, Y., & Wang, J. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00735 · Cited by 107
Self-citationDrug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond
Matthew, A. N., Leidner, F., Lockbaum, G. J., Henes, M., Zephyr, J., Hou, S., Rao, D. N., Timm, J., Rusere, L. N., Ragland, D. A., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00648 · Cited by 101
Deng, X., John, S. E. S., Osswald, H. L., O’Brien, A., Banach, B. S., Sleeman, K., Ghosh, A. K., Mesecar, A. D., & Baker, S. C. (2014) · Journal of Virology · doi:10.1128/jvi.01528-14 · Cited by 100
Self-citationComparison of antiviral resistance across acute and chronic viral infections
Mason, S. W., DeVincenzo, J. P., Toovey, S., Wu, J. Z., & Whitley, R. J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.07.020 · Cited by 83
Put a cork in it: Plugging the M2 viral ion channel to sink influenza
Jalily, P. H., Duncan, M. C., Fedida, D., Wang, J., & Tietjen, I. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104780 · Cited by 82
Self-citationFunctional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
Iketani, S., Hong, S. J., Sheng, J., Bahari, F., Culbertson, B., Atanaki, F. F., Aditham, A. K., Kratz, A., Luck, M. I., Tian, R., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.08.003 · Cited by 60
Rosenke, K., Lewis, M. C., Feldmann, F., Bohrnsen, E., Schwarz, B. H., Okumura, A., Bohler, F., Callison, J. A., Shaia, C., Bosio, C. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.166485 · Cited by 49
Sasi, V. M., Ullrich, S., Ton, J., Fry, S. E., Johansen‐Leete, J., Payne, R. J., Nitsche, C., & Jackson, C. J. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00489 · Cited by 45
Abe, K., Kabe, Y., Uchiyama, S., Iwasaki, Y. W., Ishizu, H., Uwamino, Y., Takenouchi, T., Uno, S., Ishii, M., Maruno, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-022-05424-3 · Cited by 42
Cited by
Generative artificial intelligence performs rudimentary structural biology modeling
Ille, A. M., Markosian, C., Burley, S. K., Mathews, M. B., Pasqualini, R., & Arap, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-69021-2 · Cited by 16
Metadata
- Authors
- Hu, Y., Lewandowski, E. M., Tan, H., Zhang, X., Morgan, R. T., Zhang, X., Jacobs, L. M. C., Butler, S. G., Gongora, M. V., Choy, J., Deng, X., Chen, Y., & Wang, J.
- Venue
- ACS Central Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-07-24
- Volume
- 9
- Issue
- 8
- Pages
- 1658-1669
- ISSN
- 2374-7943 (ISSN-L)
- 2374-7951
- OpenAlex
- W4385215555
- Cited by
- 333
- References
- 37
- FWCI
- 58.86
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.